Invesaro

Stocks Health care PSTV

NASDAQ · Health care

Cerenome, Inc. (PSTV)

Cerenome, Inc. brought in $4.2M of revenue over the twelve months to June 30, 2026, down 21.0% from a year earlier. It posted a net loss of $26.1M. In fiscal 2025 capital spending exceeded operating cash flow by $20.8M. At June 30, 2026 it held $2.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch PSTV in 60 seconds
Price
$3.87
0.00% on the day · July 31, 2026
52-week range $2.90 to $23.43
Market cap
$29.4M
Revenue (last 12 months)
$4.2M
-21.0% year on year
Net margin
-620.7%

What Cerenome, Inc. does

Cerenome, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PSTV.

Revenue and profit by year

Revenue
FY18: $3.7M $3.7M FY18FY23: $4.9M $4.9M FY23FY24: $5.8M $5.8M FY24FY25: $5.2M $5.2M FY25
Net income
FY18: -$12.6M -$12.6M FY18FY19: -$10.9M -$10.9M FY19FY20: -$8.2M -$8.2M FY20FY21: -$13.4M -$13.4M FY21FY22: -$20.3M -$20.3M FY22FY23: -$13.3M -$13.3M FY23FY24: -$13M -$13M FY24FY25: -$22.4M -$22.4M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$5.2M-$15.3M-$22.4M-$0.29-$20.8M
2024$5.8M-$14.7M-$13M-$2.34-$10.7M
2023$4.9M-$13.3M-$13.3M-$4.24-$13M
2022n/a-$19.7M-$20.3M-$11.58n/a
2021n/a-$12.5M-$13.4M-$16.69n/a
2020n/a-$9.6M-$8.2M-$27.97n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where PSTV ranks in Health care

Revenue$5.2M
#506 of 646 in Health care · Bottom 22%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Cerenome, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 10, 2026
  2. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue fell 70% to $411K versus the same quarter last year; diluted EPS -$1.31 versus -$0.16.
  3. August 14, 2026
  4. August 4, 2026
  5. June 18, 2026
  6. June 5, 2026
  7. June 5, 2026
  8. June 2, 2026
  9. May 15, 2026
  10. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026Revenue fell 2.9% to $1M versus the same quarter last year; diluted EPS -$1.05 versus -$29.86.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 1, 2026. Insider transactions on SEC

Insider trades

What the people running Cerenome, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 11 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
July 1, 2026 Clowes HowardDirector Exercised options 922 - - Form 4
July 1, 2026 Hedrick Marc HChief Executive Officer, Director Exercised options 6,387 - - Form 4
July 1, 2026 Hedrick Marc HChief Executive Officer, Director Exercised options 8,066 - - Form 4
July 1, 2026 Hedrick Marc HChief Executive Officer, Director Exercised options 1,986 - - Form 4
July 1, 2026 van Es-Johansson AnDirector Exercised options 922 - - Form 4
July 1, 2026 Guse KyleDirector Exercised options 922 - - Form 4
July 1, 2026 Hawkins Richard JDirector Exercised options 922 - - Form 4
July 1, 2026 Sims Andrew John Hugh MacIntyreChief Financial Officer Exercised options 1,533 - - Form 4
July 1, 2026 Sims Andrew John Hugh MacIntyreChief Financial Officer Exercised options 1,165 - - Form 4
July 1, 2026 Sims Andrew John Hugh MacIntyreChief Financial Officer Exercised options 287 - - Form 4
July 1, 2026 Andrews Ronald AsburyDirector Exercised options 922 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PSTV

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Highbridge Capital Management, LLC13G, passive 7.1% 13,157,894 May 15, 2026

Latest filings below 5%: CVI Investments, Inc. 4.9% (May 15, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

7 insiders reported holding 60,700 shares in total, about $234.9K at the last price.

HolderSharesAs of
Hedrick Marc HChief Executive Officer, Director 44,483 July 1, 2026
Sims Andrew John Hugh MacIntyreChief Financial Officer 9,941 July 1, 2026
Clowes HowardDirector 1,981 July 1, 2026
Hawkins Richard JDirector 1,529 July 1, 2026
Guse KyleDirector 922 July 1, 2026
Andrews Ronald AsburyDirector 922 July 1, 2026
van Es-Johansson AnDirector 922 July 1, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PSTV

What does Cerenome, Inc. do?

Cerenome, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PSTV.

Is Cerenome, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $26.1M on revenue of $4.2M.

How much revenue does Cerenome, Inc. make?

Over the twelve months to June 30, 2026 Cerenome, Inc. reported revenue of $4.2M. That is 21.0% less than a year earlier.

When did Cerenome, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 10, 2026.

Similar companies

Compare PSTV with

Compare PSTV with any company

Follow PSTV

Get an email when Cerenome, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PSTV: get an email when it files

Where the numbers come from

Financial figures are the values Cerenome, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.